HLA-DRB1*15:01 drives sex- and age-dependent microglial immune phenotypes and neuroimmune signaling - Scorecard - MDSpire

HLA-DRB1*15:01 drives sex- and age-dependent microglial immune phenotypes and neuroimmune signaling

  • By

  • Elsa M. Reyes-Reyes

  • Dhanalakshmi Chinnasamy

  • Michael D. Trial

  • Fernando Fernandez

  • Vincent D. Nguyen

  • Qianying He

  • Angel-Grace Leslie

  • Jessica Begay

  • Jessica Triplett

  • David Bradford

  • Carolina Figueroa

  • Jean P. Wiegand

  • Kathleen E. Rodgers

  • June 16, 2026

  • 0 min

Share

Clinical Scorecard: The Influence of HLA-DRB1*15:01 on Microglial Immune Profiles and Neuroimmune Communication Across Age and Sex

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationIndividuals with HLA-DRB1*15:01 allele, particularly older females.
Care Setting

Key Highlights

  • Remove unsupported claims.

Guideline-Based Recommendations

Diagnosis

    Management

    • Revise to include only recommendations directly supported by the source.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Patients with HLA-DRB1*15:01 allele, particularly older females.

        Focus on managing neuroinflammation and cognitive decline.

        Clinical Best Practices

        • Ensure all practices are directly supported by the source material.

        Related Resources & Content

        Original Source(s)

        HLA-DRB1*15:01 drives sex- and age-dependent microglial immune phenotypes and neuroimmune signaling

        • by Elsa M. Reyes-Reyes, Dhanalakshmi Chinnasamy, Michael D. Trial, Fernando Fernandez, Vincent D. Nguyen, Qianying He, Angel-Grace Leslie, Jessica Begay, Jessica Triplett, David Bradford, Carolina Figueroa, Jean P. Wiegand, Kathleen E. Rodgers

        • June 16, 2026

        Related Content

        FDA Approves Low-Dose Macrocyclic Contrast Agent for MRI

        The macrocyclic gadolinium-based contrast agent has a recommended dose of 0.01 mmol/kg actual body weight.

        Disease outcomes with ublituximab in treatment-naïve participants: subpopulation analyses of the phase 3 ULTIMATE I and II studies in participants with relapsing multiple sclerosis

        Menopause and ageing in women with multiple sclerosis